Skip to main content
European Commission logo
polski polski
CORDIS - Wyniki badań wspieranych przez UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Zawartość zarchiwizowana w dniu 2024-06-18

Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in the early clinical development

Cel

PHARMA-COG aims to develop a new integrated model to accelerate the development of drug cindidates for MS, PKD and AD. The innovation relies on a 'multidimensional matrix' approach, integrating all available and renewed inputs (biomarkers/animal, human models/physiological and pharmcological challenges, Phase 0/1/1b to reduce the attrition rate, to allow an early and pertinent GO/NOGO decision before entering phase II trials for both symptomatic treatment and disease modifiers approaches. The hypothesis is that effective long term drugs will normalize markers artificially modified. The general objective is to test the efficiency of the 'matrix' on drug candidates for the enhancement/protection of cognitive functions. the final objective is to improve the detection and selection of new drugs candidates within a shorter teim-frame.
Our consortium gathers 13 academics and clinicians, 8 SMEs, 1 European patient organization (Alzheimer Europe) as well as 1 regulatory body (EMEA), coming form six different EU Members States. Excellence Centres gather representatives of the different sectors: biomarkers (proteomics, transcriptomics), pharmacodynamic markers ( electrophysiology, psychophysiology, morphological and functional imaging), preclinical model specialists (cellular, transgenic mouse, monkey), clinicians, and clinical pharmacologists.
By the end of this (-year project, the following achievements are expected; definition of the most predictive combination of pharmacodynamic markers; validation of parallel models (in healthy volunteers, ApoE 4 subjects,patients and animals) to establish effective exposure ranges and support proof of mechanism studies. The predictive value of the 'matrix' will be evaluated using different pharmacological target acting drugs. Suugestions for revised/new recomendations and guidellines will help to standardize the pre-clinical and clinical phases of drugs' development in neurodegenerative diseases.

Dziedzina nauki

Not validated

Program(-y)

Temat(-y)

Zaproszenie do składania wniosków

IMI-JU-01-2008
Zobacz inne projekty w ramach tego zaproszenia

System finansowania

JTI-CP-IMI - Joint Technology Initiatives - Collaborative Project (IMI)

Koordynator

GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED
Wkład UE
Brak danych
Adres
79 NEW OXFORD STREET,
WC1A 1DG LONDON
Zjednoczone Królestwo

Zobacz na mapie
Region
London Inner London — West Camden and City of London
Rodzaj działalności
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt administracyjny
Graham Ian Somers (Dr.)
Kierownik naukowy
Jill C Richardson (Dr.)
Linki
Koszt całkowity
Brak danych

Uczestnicy (37)

Udostępnij tę stronę

Pobierz

Ostatnia aktualizacja: 5 Kwietnia 2023

Moja broszura

Permalink: https://cordis.europa.eu/project/id/115009/pl

European Union, 2024